10x Genomics, Inc. (TXG) Gross Margin
- Gross margin · 12 months: Value 70.03%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 70.03% | Gross profit / revenue. Period ending 2026-06-30. $432.03M ÷ $616.91M × 100 ≈ 70.03% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 432.03M USD | Gross Profit |
| Revenue | 616.91M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $432.03M | $616.91M | (m) | 70.03% |
| 2026-03-31 | $444.61M | $638.78M | (m) | 69.60% |
| 2025-12-31 | $443.88M | $642.82M | (m) | 69.05% |
| 2025-09-30 | $441.79M | $641.81M | (m) | 68.83% |
| 2025-06-30 | $447.88M | $644.47M | (m) | 69.50% |
| 2025-03-31 | $427.01M | $624.66M | (m) | 68.36% |
| 2024-12-31 | $414.48M | $610.78M | (m) | 67.86% |
| 2024-09-30 | $419.31M | $629.74M | (m) | 66.58% |
| 2024-06-30 | $408.44M | $631.73M | (m) | 64.65% |
| 2024-03-31 | $403.84M | $625.45M | (m) | 64.57% |
| 2023-12-31 | $409.31M | $618.73M | (m) | 66.15% |
| 2023-09-30 | $412.94M | $590.98M | (m) | 69.87% |
| 2023-06-30 | $418.10M | $568.41M | (m) | 73.56% |
| 2023-03-31 | $405.39M | $536.20M | (m) | 75.61% |
| 2022-12-31 | $396.02M | $516.41M | (m) | 76.69% |
| 2022-09-30 | $392.55M | $503.71M | (m) | 77.93% |
| 2022-06-30 | $392.63M | $497.93M | (m) | 78.85% |
| 2022-03-31 | $416.66M | $499.17M | (m) | 83.47% |
| 2021-12-31 | $416.40M | $490.49M | (m) | 84.89% |
| 2021-09-30 | $393.79M | $459.18M | (m) | 85.76% |
| 2021-06-30 | $350.42M | $405.70M | (m) | 86.37% |
| 2021-03-31 | $272.34M | $332.76M | (m) | 81.84% |
| 2020-12-31 | $240.38M | $298.85M | (m) | 80.44% |
| 2020-09-30 | $205.76M | $261.92M | (m) | 78.56% |
| 2020-06-30 | $194.08M | $251.31M | (m) | 77.23% |
| 2020-03-31 | $202.04M | $264.22M | (m) | 76.47% |
| 2019-12-31 | $184.86M | $245.89M | (m) | 75.18% |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | $147.45M | $196.56M | (m) | 75.01% |
| 2019-03-31 | $133.83M | $172.48M | (m) | 77.59% |
| 2018-12-31 | $117.65M | $146.31M | (m) | 80.41% |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | $60.52M | $71.08M | (m) | 85.14% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.